IOVA

#1519
Iovance Biotherapeutics, Inc. - Common Stock
8.7 1 USD
+0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
8.55
8.72
Jahresspanne
1.76
9.36
Tagesänderung
+1.04%
Monatliche Änderung
+98.41%
6 month change
+128.61%
Jahresänderung
+295.91%
Vorheriger Schlusskurs
8.6 2
Open
8.6 2
Tief
8.5 5
Hoch
8.7 2
Volumen
3 311
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
IOVANCE BIOTHERAPEUTICS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
IOVANCE BIOTHERAPEUTICS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
IOVANCE BIOTHERAPEUTICS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
IOVANCE BIOTHERAPEUTICS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IOVANCE BIOTHERAPEUTICS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IOVANCE BIOTHERAPEUTICS, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
IOVANCE BIOTHERAPEUTICS, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
IOVANCE BIOTHERAPEUTICS, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
IOVANCE BIOTHERAPEUTICS, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
IOVANCE BIOTHERAPEUTICS, INC. current report, Q1 FY2026
8-K

IOVANCE BIOTHERAPEUTICS, INC. current report, Q2 FY2021

Full document

Business Context and Reporting Period

Company: IOVANCE BIOTHERAPEUTICS, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: May 18, 2021
Reporting Period: Events occurring on May 18, 2021, and May 19, 2021.
Business Context: The filing reports regulatory and clinical data updates regarding the Company's lead product candidate, lifileucel, a tumor-infiltrating lymphocyte (TIL) therapy.

Key Financial Metrics

This Form 8-K is a current report regarding specific corporate events and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes

The filing discloses two material events related to the development of lifileucel:

  • Regulatory Update (May 18, 2021): The Company issued a press release providing an update on lifileucel potency assays.
  • Clinical Data Update (May 19, 2021): The Company announced clinical data updates for lifileucel in advanced melanoma, scheduled for presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.

Guidance, Outlook, and Risks

Management Commentary: The filing incorporates by reference two press releases (Exhibits 99.1 and 99.2) containing the full details of the regulatory and clinical updates. No specific financial guidance or forward-looking projections are included in the body of this 8-K.

Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the inherent uncertainties associated with the regulatory and clinical development updates referenced.

Investor Verification Checklist

  • Review Exhibit 99.1 for the full text of the May 18, 2021 press release regarding lifileucel potency assays.
  • Review Exhibit 99.2 for the full text of the May 19, 2021 press release detailing clinical data for advanced melanoma.
  • Monitor the upcoming ASCO 2021 Annual Meeting for the presentation of the announced clinical data.
  • Verify the status of the regulatory pathway for lifileucel based on the potency assay updates.

Nachrichten